Literature DB >> 9882321

Intron retention may regulate expression of Epstein-Barr virus nuclear antigen 3 family genes.

N Kienzle1, D B Young, D Liaskou, M Buck, S Greco, T B Sculley.   

Abstract

The nuclear antigen 3 family genes (EBNA-3, EBNA-4, and EBNA-6) of Epstein-Barr virus (EBV) are important for EBV-induced immortalization and survival of B lymphocytes. However, little is known about how the expression of these genes is regulated. Each of the EBNA-3, EBNA-4, and EBNA-6 genes consists of two exons separated by a small intron. Reverse transcriptase PCR assays revealed that the vast majority of the EBNA-3, EBNA-4, and EBNA-6 mRNA, expressed in transfected and EBV-infected B cells, retained intron sequences. Northern blot and S1 protection assays confirmed that most of the EBNA-3 mRNA contained intron. Examination of deletion mutants of EBNA-3 indicated that the EBNA-3 protein was not necessary for intron retention and that there was no splicing silencing element encoded in the EBNA-3 mRNA. Cell fractionation and RNA gradient analysis revealed that the unspliced EBNA 3 family mRNAs were transported into the cytoplasm and associated with the polysomes. However, Western blot analysis of FLAG-epitope tagged EBNA-3 gave no indication of the presence of splice variant protein forms of EBNA-3. In contrast, transiently transfected cells expressing EBNA-3 revealed a sixfold increase in EBNA-3 protein expression from the genomic EBNA-3 gene compared to EBNA-3 cDNA. These data show that the intronic sequences can influence EBNA-3 protein expression and suggest that intron retention may provide a means for the fine-tuning of expression of the individual EBNA 3 family genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882321      PMCID: PMC103940     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Exon definition may facilitate splice site selection in RNAs with multiple exons.

Authors:  B L Robberson; G J Cote; S M Berget
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

2.  Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes.

Authors:  J Sample; E Kieff
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Both A type and B type Epstein-Barr virus nuclear antigen 6 interact with RBP-2N.

Authors:  D B Young; K Krauer; N Kienzle; T Sculley
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

4.  The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels.

Authors:  W Hammerschmidt; B Sugden; V R Baichwal
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

Review 5.  Alternative splicing in the control of gene expression.

Authors:  C W Smith; J G Patton; B Nadal-Ginard
Journal:  Annu Rev Genet       Date:  1989       Impact factor: 16.830

Review 6.  On/off regulation of gene expression at the level of splicing.

Authors:  P M Bingham; T B Chou; I Mims; Z Zachar
Journal:  Trends Genet       Date:  1988-05       Impact factor: 11.639

7.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

8.  Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes.

Authors:  M Woisetschlaeger; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75).

Authors:  H Ben-Bassat; N Goldblum; S Mitrani; T Goldblum; J M Yoffey; M M Cohen; Z Bentwich; B Ramot; E Klein; G Klein
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

10.  Regulation of Rous sarcoma virus RNA splicing and stability.

Authors:  S Arrigo; K Beemon
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

View more
  7 in total

1.  Epstein-Barr virus-encoded RK-BARF0 protein expression.

Authors:  N Kienzle; M Buck; S Greco; K Krauer; T B Sculley
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes.

Authors:  Elena Kashuba; Mariya Yurchenko; Surya Pavan Yenamandra; Boris Snopok; Maria Isaguliants; Laszlo Szekely; George Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

Review 3.  Intron retention in viruses and cellular genes: Detention, border controls and passports.

Authors:  David Rekosh; Marie-Louise Hammarskjold
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-03-06       Impact factor: 9.957

4.  Translational profiling of B cells infected with the Epstein-Barr virus reveals 5' leader ribosome recruitment through upstream open reading frames.

Authors:  Maja Bencun; Olaf Klinke; Agnes Hotz-Wagenblatt; Severina Klaus; Ming-Han Tsai; Remy Poirey; Henri-Jacques Delecluse
Journal:  Nucleic Acids Res       Date:  2018-04-06       Impact factor: 16.971

5.  Computational analysis of splicing errors and mutations in human transcripts.

Authors:  Yerbol Z Kurmangaliyev; Mikhail S Gelfand
Journal:  BMC Genomics       Date:  2008-01-14       Impact factor: 3.969

Review 6.  Intron Retention as a Mode for RNA-Seq Data Analysis.

Authors:  Jian-Tao Zheng; Cui-Xiang Lin; Zhao-Yu Fang; Hong-Dong Li
Journal:  Front Genet       Date:  2020-07-07       Impact factor: 4.599

7.  Genetic Patterns Found in the Nuclear Localization Signals (NLSs) Associated with EBV-1 and EBV-2 Provide New Insights into Their Contribution to Different Cell-Type Specificities.

Authors:  Louise Zanella; María Elena Reyes; Ismael Riquelme; Michel Abanto; Daniela León; Tamara Viscarra; Carmen Ili; Priscilla Brebi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.